Safety and Feasibility of the Lung Volume Reduction Reverser System in Patients with Severe Emphysema: A First-in-Human Pilot Study
Respiration · 17.11.2026 · 105 (10) · 1130-1140
DOI: 10.1159/000551022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respiration, online erschienen am 24.03.2026. Verfasst von A Susanne Dittrich und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pneumology and Critical Care Medicine, Thoraxklinik at the University Hospital Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Pulmonary Emphysema, Pneumonectomy, Pulmonary Disease, Chronic Obstructive. Die Arbeit nennt 29 Literaturangaben. Gefördert von: LifeTech Scientific Co., Ltd (Shenzen, China).
Abstract (Originalsprache)
Introduction
Endoscopic lung volume reduction with coils is a symptomatic treatment approach for patients with severe pulmonary emphysema and positive collateral ventilation. In this study, we evaluated the safety and feasibility of the new Lung Volume Reduction Reverser (LVR-R) system.
Methods
Prospective, nonrandomized, exploratory, single-center, first-in-man study in 15 patients with chronic obstructive pulmonary disease (COPD) and severe emphysema. Most affected lung lobes were treated sequentially with the LVR-R coils from May 2019 to JUL 2022. Pulmonary function, 6-min walking distance (6-MWD), questionnaires and adverse events were recorded from baseline to 1-year post-procedure. Computer tomography was acquired at baseline and 6 months.
Results
A total of 28 procedures were performed, in which 10 (n = 22, 78.6%), 9 (n = 2, 7.1%), or 8 (n = 4, 14.3%) LVR-R coils were implanted, predominantly in the upper lobes (n = 26/28, 92.86%). Two patients refused a second treatment, one of whom refused follow-ups. Adverse events at 3 months included severe pneumonia and/or COPD exacerbations (n = 7), ventilatory failure (n = 2) and 1 pneumothorax requiring thoracic drainage. Mild hemoptysis occurred in 18 and mild pneumonia and/or COPD exacerbations in 9 patients. Overall, neither FEV1, residual volume, 6-MWD, CAT nor mMRC improved within 1-year (n.s. all). In 2 patients, response in FEV1 >500 mL occurred.
Conclusion
In this severely diseased and small patient cohort, LVR-R implantation was technically feasible. The complication rate was similar to other coil studies and requires a careful pre-procedure benefit-risk evaluation. Two of fourteen bilaterally treated individuals demonstrated a notable improvement in lung function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pneumology and Critical Care Medicine, Thoraxklinik at the University Hospital Heidelberg, Heidelberg, Germany.
- Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
- Department of Diagnostic and Interventional Radiology, Thoraxklinik at the University Hospital Heidelberg, Heidelberg, Germany.
- Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.
- Pneumology and Critical Care Medicine, Asklepios Klinik Barmbek, Hamburg, Germany.
Förderung
- LifeTech Scientific Co., Ltd (Shenzen, China)
Zitieren
APA
Dittrich, A. S., Brock, J. M., Heussel, C. P., Herth, F. J. F., Eberhardt, R., & Kontogianni, K. (2026). Safety and Feasibility of the Lung Volume Reduction Reverser System in Patients with Severe Emphysema: A First-in-Human Pilot Study. Respiration, 105(10), 1130-1140. https://doi.org/10.1159/000551022
Vancouver
Dittrich AS, Brock JM, Heussel CP, Herth FJF, Eberhardt R, Kontogianni K. Safety and Feasibility of the Lung Volume Reduction Reverser System in Patients with Severe Emphysema: A First-in-Human Pilot Study. Respiration. 2026;105(10):1130-1140. doi:10.1159/000551022
BibTeX
@article{Dittrich2026,
author = {Dittrich, A Susanne and Brock, Judith Maria and Heussel, Claus-Peter and Herth, Felix J F and Eberhardt, Ralf and Kontogianni, Konstantina},
title = {Safety and Feasibility of the Lung Volume Reduction Reverser System in Patients with Severe Emphysema: A First-in-Human Pilot Study},
journal = {Respiration},
year = {2026},
volume = {105},
number = {10},
pages = {1130--1140},
doi = {10.1159/000551022}
}
EUVIMED